Money
Briefing: This is What Merck & Co. (MRK) is Doing to Mitigate Against KEYTRUDA Exclusivity Loss
Strategic angle: Merck & Co. is taking strategic steps to address the impending loss of exclusivity for KEYTRUDA.
editorial-staff
1 min read
Updated 27 days ago
As KEYTRUDA nears the end of its exclusivity period, Merck & Co. is implementing strategic initiatives aimed at maintaining its market position.
These measures are likely to include enhancements in operational capacity and adjustments in product offerings to mitigate potential revenue impacts.
The company's approach reflects a broader trend in the pharmaceutical industry, where firms are increasingly focused on sustaining competitive advantages in the face of patent expirations.